AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 291: H886-H893, 2006. First published April 7, 2006; doi:10.1152/ajpheart.00142.2006
0363-6135/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/2/H886    most recent
00142.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, M.
Right arrow Articles by Hamano, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, M.
Right arrow Articles by Hamano, K.

Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury

Masaya Takahashi, Tao-Sheng Li, Ryo Suzuki, Toshiro Kobayashi, Hiroshi Ito, Yasuhiro Ikeda, Masunori Matsuzaki, and Kimikazu Hamano

Department of Medical Bioregulation, Division of Cardiovascular Surgery and Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

Submitted 7 February 2006 ; accepted in final form 17 March 2006

It is well known that the implantation of bone marrow mononuclear cells (BM-MNCs) into ischemic hearts can induce angiogenesis and improve cardiac function after myocardial infarction, but the precise mechanisms of these actions are unclear. We hypothesize that the cytokines produced by BM-MNCs play a key role in this cell-based therapy. BM-MNCs from rats were cultured under normoxic or hypoxic (1% O2) conditions for 24 h, and then supernatants were collected for study. ELISA and Western blotting analysis showed that various cytokines, including VEGF, IL-1beta, PDGF, and IGF-1, were produced from BM-MNCs, some of which were enhanced significantly under hypoxia stimulation. When compared with a control blank medium, the supernatants of BM-MNCs cultured under normoxic or hypoxic conditions inhibited apoptosis significantly and preserved the contractile capacity of isolated adult rat cardiomyocytes in vitro (P < 0.05). Using a rat model of acute myocardial infarction, we injected the supernatants of BM-MNCs or control medium intramyocardially on day 0 and then intraperitoneally on days 2, 4, and 6 after infarction. When compared with the control medium, the supernatants of BM-MNCs cultured under both normoxic or hypoxic conditions increased the microvessel density and decreased the fibrotic area in the infarcted myocardium significantly, contributing to remarkable improvement in cardiac function. Various cytokines were produced by BM-MNCs, and these cytokines contributed to functional improvement of the infarcted heart by directly preserving the contractile capacity of the myocardium, inhibiting apoptosis of cardiomyocytes, and inducing therapeutic angiogenesis of the infarcted heart.

ischemia; angiogenesis; bone marrow mononuclear cell; cytokine; apoptosis


Address for reprint requests and other correspondence: T.-S. Li, Dept. of Medical Bioregulation, Yamaguchi Univ. School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan (e-mail: litaoshe{at}yamaguchi-u.ac.jp)




This article has been cited by other articles:


Home page
 Eur Heart JHome page
V. K. Lai, K.-L. Ang, W. Rathbone, N. J. Harvey, and M. Galinanes
Randomized controlled trial on the cardioprotective effect of bone marrow cells in patients undergoing coronary bypass graft surgery
Eur. Heart J., October 1, 2009; 30(19): 2354 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Shabbir, D. Zisa, G. Suzuki, and T. Lee
Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1888 - H1897.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Kamota, T.-S. Li, N. Morikage, M. Murakami, M. Ohshima, M. Kubo, T. Kobayashi, A. Mikamo, Y. Ikeda, M. Matsuzaki, et al.
Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase.
J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1814 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
H. Mollmann, H. Nef, A. Elsasser, and C. Hamm
Stem cells in myocardial infarction: from bench to bedside
Heart, March 15, 2009; 95(6): 508 - 514.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Q. Zhao, Y. Sun, L. Xia, A. Chen, and Z. Wang
Randomized Study of Mononuclear Bone Marrow Cell Transplantation in Patients With Coronary Surgery
Ann. Thorac. Surg., December 1, 2008; 86(6): 1833 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Gnecchi, Z. Zhang, A. Ni, and V. J. Dzau
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy
Circ. Res., November 21, 2008; 103(11): 1204 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
X. Hu, S. P. Yu, J. L. Fraser, Z. Lu, M. E. Ogle, J.-A. Wang, and L. Wei
Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis.
J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 799 - 808.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.